T. Bakker
Risk assessmentInternal medicineRheumatologyMedDRAVedolizumabInfliximabEtanerceptRheumatoid arthritisDiscontinuationDepression (differential diagnoses)Adverse drug reactionPopulationDrug reactionIn patientLow dose methotrexateFamily medicineClinical trialMedicine
2Publications
0Citations
Publications 2
Newest
Source
Background: Chronic fatigue is a well-known symptom in patients with rheumatic diseases and other immune-mediated inflammatory diseases (IMIDs). Therefore, fatigue as an adverse drug reaction (ADR) to biologics may remain unrecognised or may erroneously be attributed to the disease. Objectives: To assess patient-reported fatigue attributed to biologics for IMIDs and investigate predisposing factors of patient-reported fatigue. Methods: The Dutch Biologic Monitor is a multicenter patient-reported...
Source